文献速递产科

早期宫内球囊填塞对阴道分娩后即刻产后出血的疗效:一项随机临床试验

Efficacy of early intrauterine balloon tamponade for immediate postpartum hemorrhage after vaginal delivery: a randomized clinical trial.
PubMed 文献 · Am J Obstet Gynecol · 2023-05-18

这项多中心随机对照试验纳入403名阴道分娩后一线宫缩剂治疗失败的产后出血产妇,比较宫内球囊填塞联用二线宫缩剂与二线宫缩剂失败后再用球囊填塞对严重产后出血发生率的影响。结果显示,研究组主要结局发生率为67.2%(131/195),对照组为74.3%(142/191),风险比0.90(95%CI 0.79-1.03)。结论认为早期使用宫内球囊填塞并未降低严重产后出血的发生率。

要点

  • 研究组严重产后出血发生率为67.2%(131/195),对照组为74.3%(142/191),风险比0.90(95%CI 0.79-1.03)。
  • 计算性围产期失血量≥1500 mL、任何输血、侵入性操作及转入重症监护室的发生率两组间无显著差异。
  • 研究组子宫内膜炎发生5例(2.7%),对照组无发生(P=.06)。

核心结论

  • 与二线宫缩剂治疗失败后、侵入性操作前使用宫内球囊填塞相比,早期使用宫内球囊填塞并未降低严重产后出血的发生率。

研究设计与样本

  • 多中心、随机、对照、平行组、非盲临床试验,在18家医院开展,纳入403名阴道分娩、孕35至42周的产妇。
  • 纳入标准为一线宫缩剂(缩宫素)治疗失败的产后出血且需二线宫缩剂舒普罗酮(E1前列腺素)治疗。
  • 研究组在随机化后15分钟内行舒普罗酮输注联合ebb球囊宫内填塞;对照组在随机化后15分钟内单独开始舒普罗酮输注,若输注开始后30分钟出血持续则行ebb球囊宫内填塞。
  • 两组若球囊置入后30分钟出血持续,则行急诊放射学或外科侵入性操作。
  • 排除11名符合排除标准或撤回知情同意者后,研究组199名、对照组193名纳入意向性治疗分析。

主要发现

  • 主要结局(接受≥3单位浓缩红细胞或计算性围产期失血量>1000 mL)在研究组195名中发生131名(67.2%),对照组191名中发生142名(74.3%),风险比0.90(95%CI 0.79-1.03)。
  • 计算性围产期失血量≥1500 mL、任何输血、侵入性操作及转入重症监护室的发生率两组间无显著差异。
  • 研究组子宫内膜炎发生5名(2.7%),对照组无发生(P=.06)。
  • 研究组4名、对照组2名因缺少计算主要结局所需的围产期血细胞比容变化数据。
  • 第八次中期分析时独立数据监测委员会认定主要结局发生率两组间无差异并停止入组。

关键数值与推荐

  • 主要结局为接受≥3单位浓缩红细胞或计算性围产期失血量>1000 mL的产妇比例。
  • 预设次要结局为计算性失血量≥1500 mL、任何输血、侵入性操作及转入重症监护室的产妇比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many questions remain about the appropriate use of intrauterine balloon devices in postpartum hemorrhage after vaginal delivery refractory to first-line uterotonics. Available data suggest that early use of intrauterine balloon tamponade might be beneficial. OBJECTIVE: This study aimed to compare the effect of intrauterine balloon tamponade used in combination with second-line uterotonics vs intrauterine balloon tamponade used after the failure of second-line uterotonic treatment on the rate of severe postpartum hemorrhage in women with postpartum hemorrhage after vaginal delivery refractory to first-line uterotonics. STUDY DESIGN: This multicenter, randomized, controlled, parallel-group, nonblinded trial was conducted at 18 hospitals and enrolled 403 women who had just given birth vaginally at 35 to 42 weeks of gestation. The inclusion criteria were a postpartum hemorrhage refractory to first-line uterotonics (oxytocin) and requiring a second-line uterotonic treatment with sulprostone (E1 prostaglandin). In the study group, the sulprostone infusion was combined with intrauterine tamponade by an ebb balloon performed within 15 minutes of randomization. In the control group, the sulprostone infusion was started alone within 15 minutes of randomization, and if bleeding persisted 30 minutes after the start of sulprostone infusion, intrauterine tamponade using the ebb balloon was performed. In both groups, if the bleeding persisted 30 minutes after the insertion of the balloon, an emergency radiological or surgical invasive procedure was performed. The primary outcome was the proportion of women who either received ≥3 units of packed red blood cells or had a calculated peripartum blood loss of >1000 mL. The prespecified secondary outcomes were the proportions of women who had a calculated blood loss of ≥1500 mL, any transfusion, an invasive procedure and women who were transferred to the intensive care unit. The analysis of the primary outcome with the triangular test was performed sequentially throughout the trial period. RESULTS: At the eighth interim analysis, the independent data monitoring committee concluded that the incidence of the primary outcome did not differ between the 2 groups and stopped inclusions. After 11 women were excluded because they met an exclusion criterion or withdrew their consent, 199 and 193 women remained in the study and control groups, respectively, for the intention-to-treat analysis. The women's baseline characteristics were similar in both groups. Peripartum hematocrit level change, which was needed for the calculation of the primary outcome, was missing for 4 women in the study group and 2 women in the control group. The primary outcome occurred in 131 of 195 women (67.2%) in the study group and 142 of 191 women (74.3%) in the control group (risk ratio, 0.90; 95% confidence interval, 0.79-1.03). The groups did not differ substantially for rates of calculated peripartum blood loss pf ≥1500 mL, any transfusion, invasive procedure, and admission to an intensive care unit. Endometritis occurred in 5 women (2.7%) in the study group and none in the control group (P=.06). CONCLUSION: The early use of intrauterine balloon tamponade did not reduce the incidence of severe postpartum hemorrhage compared with its use after the failure of second-line uterotonic treatment and before recourse to invasive procedures.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rozenberg P, Sentilhes L, Goffinet F, et al. Efficacy of early intrauterine balloon tamponade for immediate postpartum hemorrhage after vaginal delivery: a randomized clinical trial. Am J Obstet Gynecol. 2023. PMID: 37209893. doi:10.1016/j.ajog.2023.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。